Arrowhead PharmaceuticalsMEX:ARWR 49 Net Current Asset Value is MXN23.79 as of Mar. 2026, which is 100% below its 10-year median of 20.82. GuruFocus rates MEX:ARWR with a GF Score™ of 49/100 and a GF Value™ of MXN270.21. The stock has 7 warning signs investors should review. Among 942 Biotechnology companies, Arrowhead Pharmaceuticals ranks worse than 95.97% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Arrowhead Pharmaceuticals's net current asset value per share for the quarter that ended in Mar. 2026 was MXN23.79.
The historical rank and industry rank for Arrowhead Pharmaceuticals's Net Current Asset Value or its related term are showing as below:
MEX:ARWR'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.94 Med: 20.82 Max: 149.96
Current: 65.59
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Arrowhead Pharmaceuticals was 149.96. The lowest was 1.94. And the median was 20.82.
MEX:ARWR's Price-to-Net-Current-Asset-Value is ranked worse than 95.97% of 942
companies
in the Biotechnology industry
Industry Median: 4.88
vs MEX:ARWR: 65.59
Arrowhead Pharmaceuticals (MEX:ARWR) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Arrowhead Pharmaceuticals Net Current Asset Value Related Terms
Arrowhead Pharmaceuticals Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Arrowhead Pharmaceuticals's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arrowhead Pharmaceuticals Net Current Asset Value Chart
MEX:ARWR vs CYTK, TECH, KRYS: Net Current Asset Value Comparison
For the Biotechnology subindustry, Arrowhead Pharmaceuticals's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arrowhead Pharmaceuticals Price-to-Net-Current-Asset-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Arrowhead Pharmaceuticals's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of MXN23.79 mean?
Arrowhead Pharmaceuticals (MEX:ARWR) has a Net Current Asset Value of MXN23.79 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Arrowhead Pharmaceuticals and its competitors. This is 14% above median its historical median of 20.82. Over the past decade, Arrowhead Pharmaceuticals' Net Current Asset Value has ranged from 1.94 to 149.96. According to the industry distribution chart, Arrowhead Pharmaceuticals ranks #904 out of 942 companies in the Biotechnology industry, placing it in the top 96%.
Is Arrowhead Pharmaceuticals' Net Current Asset Value too high?
Arrowhead Pharmaceuticals' current Net Current Asset Value of MXN23.79 is 14% above median its 10-year median of 20.82. Over the past 10 years, this metric has ranged from a low of 1.94 to a high of 149.96. Based on the distribution chart, Arrowhead Pharmaceuticals ranks #904 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Net Current Asset Value compare to CYTK and TECH?
According to the Biotechnology industry distribution chart, Arrowhead Pharmaceuticals ranks #904 out of 942 companies for Net Current Asset Value. This places Arrowhead Pharmaceuticals in the lower half of its industry. The industry median Net Current Asset Value is 4.88. Historically, Arrowhead Pharmaceuticals' own Net Current Asset Value has ranged from 1.94 to 149.96 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Biotechnology company?
The median Net Current Asset Value among Biotechnology companies is 4.88, based on 942 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Arrowhead Pharmaceuticals and its competitors. For the Biotechnology industry, the median Net Current Asset Value is 4.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arrowhead Pharmaceuticals's current Net Current Asset Value is MXN23.79, which is 14% above median its own 10-year median of 20.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Arrowhead Pharmaceuticals (MEX:ARWR) has a current Net Current Asset Value of MXN23.79. The stock's GF Value™ is MXN270.21, compared to a current price of MXN454.55 — trading 68.2% above its estimated fair value. The current Net Current Asset Value is MXN23.79, which is 14% above median its 10-year median of 20.82. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (MEX:ARWR), the current Net Current Asset Value is MXN23.79 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arrowhead Pharmaceuticals (MEX:ARWR) Overvalued in 2026?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN454.55 is trading 68.2% above its estimated GF Value™ of MXN270.21.
Key valuation signals for MEX:ARWR:
Net Current Asset Value: MXN23.79 (14% above median its 10-year median of 20.82)
GF Value™: MXN270.21 vs. price of MXN454.55 (68.2% above fair value)
No single metric tells the full story. See the MEX:ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score
Get the complete analysis for MEX:ARWR
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ARWR has been successfully added to your 
